<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Of 386 patients with allogeneic bone marrow transplants (BMT) treated during a 9-year interval, 166 developed <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo> (IP) </plain></SENT>
<SENT sid="1" pm="."><plain>Idiopathic and cytomegalovirus (CMV) IP constituted 90% of the 113 cases in which tissue was examined </plain></SENT>
<SENT sid="2" pm="."><plain>Risk factors for IP overall were <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (AGVHD), remote transplant date, the diagnosis of <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and GVHD prophylaxis with agents other than <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Risk factors for CMV IP were pre-transplant CMV seropositivity, CMV excretion, age greater than 10 years, AGVHD, GVHD prophylaxis with agents other than <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, and a remote transplant date </plain></SENT>
<SENT sid="4" pm="."><plain>Patients transplanted for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> were at lower risk for idiopathic IP than those transplanted for <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The incidence of IP in patients given <z:chebi fb="0" ids="28901">busulfan</z:chebi> plus <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> was equivalent to that in patients receiving <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> plus total body irradiation </plain></SENT>
<SENT sid="6" pm="."><plain>The incidence of idiopathic IP remained constant over this 9-year period while CMV IP declined significantly </plain></SENT>
</text></document>